Smolen J.S., Aletaha D., BijLsma J.W., Breedveld F.C., Boumpas D., Burmester G. et al. Treating Rheumatoid Arthritis to Target: Recommendations of an international Task Force. Ann Rheum Dis. 2010;69(4):631-637. https://doi.org/ 10.1136/ard.2009.123919..
DOI: 10.1136/ard.2009.123919
Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M. et.al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2013 Update. Ann Rheum Dis. 2014;73(3):492-509. https://doi.org/10.1136/annrheumdis-2013-204573..
DOI: 10.1136/annrheumdis-2013-204573
Smolen J.S., Landewe R., Bijlsma J., Burmester G., Chatzidionysiony K., Dougados M. et al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update. Ann Rheum Dis. 2017;76(6):960-977. https://doi.org/10.1136/annrheumdis-2016-210715..
DOI: 10.1136/annrheumdis-2016-210715
Smolen J.S., Landewe R.B.M., Bijlsma WJ., Burmester G., Dougados M., Kerschbaumer A. et al. EULAR Recommendations for the Management of rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann Rheum Dis. 2020;79(6):685-699. https://doi.org/10.1136/annrheumdis-2019-216655..
DOI: 10.1136/annrheumdis-2019-216655
Насонов Е.Л. (ред.). Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2020. 448 с. Режим доступа: http://www.geotar.ru/lots/ NF0015039.html.http://www.geotar.ru/lots/
Насонов Е.Л. (ред.). Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа; 2020. 448 с. Режим доступа: http://www.geotar.ru/lots/ NF0015039.html.http://www.geotar.ru/lots/NF0015039.html
Yu C., Jin S., Wang Y., Jiang N., Wu C., Wang O. et.al. Remission Rate and Predictors of Remission in Patients with Rheumatoid Arthritis under Treat-To-Target Strategy in Real-World Studies: A Systematic Review and MetaAnalysis. Clin Rheumatol. 2019;38(3):727-738. https://doi.org/10.1007/s10067-018-4340-7..
DOI: 10.1007/s10067-018-4340-7
Aletaha D., Smolen J.S. Diagnosis and Management of Rheumatoid Arthritis. A Review. JAMA. 2018;320(13):1360-1372. https://doi.org/10.1001/jama.2018.13103..
DOI: 10.1001/jama.2018.13103
Tanaka Y., Yamanaka H., Ishiguro N., Miyasaka N., Kawana K., Kimura J. et.al. Low Disease Activity for Up to 3 Years after Adalimumab Discontinuation in Patients with Early Rheumatoid Arthritis: 2-Year Results of the HOPEFUL-3 Study. Arthritis Res Ther. 2017;19(1):56. https://doi.org/10.1186/s13075-017-1264-6..
DOI: 10.1186/s13075-017-1264-6
Steunebrink L.M., Versteeg G.A., Vonkeman H.E., Ten Klooster P.M., Kuper H.H., Zijlstra T.R. et al. Initial Combination Therapy versus Step-Up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry. Arthritis Res Ther 2016;18:60. https://doi.org/10.1186/s13075-016-0962-9..
DOI: 10.1186/s13075-016-0962-9
Kavanaugh A., van Vollenhoven R.F., Wolfe B.A., Florentinus S., Chen S., Suboticki J.L., Smolen J.S. Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: A Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab. Ann Rheum Dis. 2017;76(Suppl 2):822-823. https://doi.org/10.1136/annrheumdis-2017-eular.1892..
DOI: 10.1136/annrheumdis-2017-eular.1892
Hetland M.L., Haavardsholm E.A., Rudin A., Nordstrom D., Nurmohamed M., Gudbjornsson B. et al. Active Conventional Treatment and Three Different Biological Treatments in Early Rheumatoid Arthritis: Phase IV Investigator Initiated, Randomised, Observer Blinded Clinical Trial. BMJ. 2020;371:m4328. https://doi.org/10.1136/bmj.m4328..
DOI: 10.1136/bmj.m4328
Aletha D., Smolen J.S. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A Review of Their Usefulness and Validity in Rheumatoid Arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39): S100-S108. Available at: https://pubmed.ncbi.nlm.nih.gov/16273793/.https://pubmed.ncbi.nlm.nih.gov/16273793/
Aletha D., Smolen J.S. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A Review of Their Usefulness and Validity in Rheumatoid Arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39): S100-S108. Available at: https://pubmed.ncbi.nlm.nih.gov/16273793/.https://pubmed.ncbi.nlm.nih.gov/16273793/
Moreland L.W., ODell J.R., Paulus H.E., Curtis J.R., Bathon J.M., St Clair E.W. et al. A Randomized Comparative Effectiveness Study of Oral Triple Therapy versus Etanercept plus Methotrexate in Early Aggressive Rheumatoid Arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64(9):2824-2835. https://doi.org/10.1002/art.34498..
DOI: 10.1002/art.34498
Felson D.T., Anderson JJ., Lange M.L., Wells G., LaValley M.P. Should Improvement in Rheumatoid Arthritis Clinical Trials Be Defined as Fifty Percent or Seventy Percent Improvement in Core Set Measures, Rather Than Twenty Percent? Arthritis Rheum 1998;41(9):1564-1570. https://doi.org/10.1002/1529-0131(199809)41:9[%]3C1564::aid-art6[%]3E3.0.co;2-m..
DOI: 10.1002/1529-0131(199809)41:9[%]3C1564::aid-art6[%]3E3.0.co;2-m
Hazlewood G.S., Barnabe C., Tomlinson G., Marshall D., Devoe D., Bombardier C. Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Disease Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Abridged Cochrane Systematic Review and Network Meta-Analysis.BMJ. 2016;353:i1777. https://doi.org/10.1136/bmj.i1777..
DOI: 10.1136/bmj.i1777
Mazouyes A., Clay M., Bernard A.C., Gaudin P, Baillet A. Efficacy of Triple Association Methotrexate, Sulfasalazine and Hydroxychloroquine in Early Treatment of Rheumatoid Arthritis with Insufficient Response to Methotrexate: Meta-Analysis of Randomized Controlled Trials. Joint Bone Spine. 2017;84(5):563-570. https://doi.org/10.1016/j.jbspin.2016.10.010..
DOI: 10.1016/j.jbspin.2016.10.010
Van Vollenhoven R.F., Ernestam S., Geborek P, Petersson I.F., Coster L., Waltbrand E. et al. Addition of Infliximab Compared with Addition of Sulfasalazine and Hydroxychloroquine to Methotrexate in Patients with Early Rheumatoid Arthritis (Swefot Trial): 1-Year Results of a Randomised Trial. Lancet. 2009;374(9688):459-466. https://doi.org/10.1016/S0140-6736(09)60944-2..
DOI: 10.1016/S0140-6736(09)60944-2
Van Vollenhoven R.F., Geborek P., Forslind K., Albertsson K., Ernestam S., Petersson I.F. et al. Conventional Combination Treatment versus Biological Treatment in Methotrexate-Refractory Early Rheumatoid Arthritis: 2 Year Follow-Up of the Randomised, Non-Blinded, Parallel-Group Swefot Trial. Lancet. 2012;379(9827):1712-1720. https://doi.org/10.1016/S0140-6736(12)60027-0..
DOI: 10.1016/S0140-6736(12)60027-0
Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens PJ., Hazes J.M. et al. Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients with Early Rheumatoid Arthritis (the BeSt Study): A Randomized, Controlled Trial. Arthritis Rheum. 2005;52(11):3381-3390. https://doi.org/10.1002/art.21405..
DOI: 10.1002/art.21405
Eriksson J.K., Neovius M., Bratt J., Petersson I.F., van Vollenhoven R.F., Geborek P., Ernestam S. Biological vs. Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis: A Randomized Trial. JAMA Intern Med. 2013;173(15):1407-1414. https://doi.org/10.1001/jamainternmed.2013.7801..
DOI: 10.1001/jamainternmed.2013.7801
Yelin E. Not Better But Quite Good: Effects on Work Loss of Combination Treatment for Rheumatoid Arthritis with and without Biological Agents. JAMA Intern Med. 2013;173(15):1414-1415. https://doi.org/10.1001/jamainternmed.2013.7812..
DOI: 10.1001/jamainternmed.2013.7812
Eriksson J.K., Karlsson J.A., Bratt J., Ingemar F., Petersson I.F., van Vollenhoven R.F. et al. Cost-Effectiveness of Infliximab versus Conventional Combination Treatment in Methotrexate-Refractory Early Rheumatoid Arthritis: 2-Year Results of the Register-Enriched Randomised Controlled SWEFOT Trial. Ann Rheum Dis. 2015;74(6):1094-1101. https://doi.org/10.1136/annrheumdis-2013-205060..
DOI: 10.1136/annrheumdis-2013-205060
Scott D.L., Ibrahim F., Farewell V., OKeeffe A.G., Ma M., Walker D. et al. Randomised Controlled Trial of Tumour Necrosis Factor Inhibitors against Combination Intensive Therapy with Conventional Disease-Modifying Antirheumatic Drugs in Established Rheumatoid Arthritis: the TACIT Trial and Associated Systematic Reviews. Health Technol Assess. 2014;18(66): 1-164. https://doi.org/10.3310/hta18660..
DOI: 10.3310/hta18660
Scott D.L., Ibrahim F., Farewell V., OKeeffe A.G., Walker D., Kelly C. et al. Tumour Necrosis Factor Inhibitors versus Combination Intensive Therapy with Conventional Disease Modifying Anti-Rheumatic Drugs in Established Rheumatoid Arthritis: TACIT Non-Inferiority Randomised Controlled Trial. BMJ. 2015;350:h1046. https://doi.org/10.1136/bmj.h1046..
DOI: 10.1136/bmj.h1046
Bansback N., Phibbs C.S., Sun H., ODell J.R., Brophy M., Keystone E.C. et al. Triple Therapy versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Ann Intern Med. 2017;167(1):8-16. https://doi.org/10.7326/M16-0713..
DOI: 10.7326/M16-0713
Li S., Li J., Peng L., Li Y., Wan X. Cost-Effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure. Rheumatol Ther 2021. https://doi.org/10.1007/s40744-021-00300-4..
DOI: 10.1007/s40744-021-00300-4
Shi Z.C., Fei H.P., Wang Z.L. Cost-Effectiveness Analysis of Etanercept plus Methotrexate vs Triple Therapy in Treating Chinese Rheumatoid Arthritis Patients. Medicine (Baltimore). 2020;99(3):e16635. https://doi.org/10.1097/MD.0000000000016635..
DOI: 10.1097/MD.0000000000016635
Kay J., Schoels M.M., Dorner T., Emery P, Kvien T.K., Smolen J.S., Breedveld F.C. Consensus-Based Recommendations for the Use of Biosimilars to Treat Rheumatological Diseases. Ann Rheum Dis. 2018;77(2):165-174. https://doi.org/10.1136/annrheumdis-2017-211937..
DOI: 10.1136/annrheumdis-2017-211937
Насонов Е.Л. (ред.). Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС; 2013. 552 с.
Lethaby A., Lopez-Olivo M.A., Maxwell L., Burls A., Tugwell P, Wells G.A. Etanercept for the Treatment of Rheumatoid Arthritis. Cochrane Database Syst Rev. 2013;(5):CD004525. https://doi.org/10.1002/14651858.CD004525.pub2..
DOI: 10.1002/14651858.CD004525.pub2
Eng G., Stoltenberg M.B., Szkudlarek M., Bouchelouche P.N., Christensen R., Bliddal H., Marie Bartels E. Efficacy of Treatment Intensification with Adalimumab, Etanercept and Infliximab in Rheumatoid Arthritis: A Systematic Review of Cohort Studies with Focus on Dose. Semin Arthritis Rheum. 2013;43(2):144-151. https://doi.org/10.1016/j.semarthrit.2013.01.007..
DOI: 10.1016/j.semarthrit.2013.01.007
Buckley F., Finckh A., Huizinga T.W., Dejonckheere F., Jansen J.P. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. J Manag Care Spec Pharm. 2015;21(5):409-423. https://doi.org/10.18553/jmcp.2015.21.5.409..
DOI: 10.18553/jmcp.2015.21.5.409
Ariza-Ariza R., Navarro-Sarabia F., Hernandez-Cruz B., Rodriguez-Arboleya L., Navarro-Compan V., Toyos J. Dose Escalation of the Anti-TNF-Alpha Agents in Patients with Rheumatoid Arthritis. A Systematic Review. Rheumatology (Oxford). 2007;46(3):529-532. https://doi.org/10.1093/rheumatology/kel326..
DOI: 10.1093/rheumatology/kel326
Ariza-Ariza R., Navarro-Sarabia F., Hernandez-Cruz B., Rodriguez-Arboleya L., Navarro-Compan V., Toyos J. Dose Escalation of the Anti-TNF-Alpha Agents in Patients with Rheumatoid Arthritis. A Systematic Review. Rheumatology (Oxford). 2007;46(3):529-532. https://doi.org/10.1093/rheumatology/kel326..
DOI: 10.1093/rheu-matology/kel326
Schabert V.F., Bruce B., Ferrufino C.F., Globe D.R., Harrison DJ., Lingala B., Fries J.F. Disability Outcomes and Dose Escalation with Etanercept, Adalimumab, and Infliximab in Rheumatoid Arthritis Patients: A US-Based Retrospective Comparative Effectiveness Study. Curr Med Res Opin. 2012;28(4):569-580. https://doi.org/10.1185/03007995.2012.656844..
DOI: 10.1185/03007995.2012.656844
Moots RJ., Xavier R.M., Mok C.C., Rahman M.U., Tsai W.C., Al-Maini M.H. et al. Correction: The Impact of Anti-Drug Antibodies on Drug Concentrations and Clinical Outcomes in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab: Results from a Multinational, Real-World Clinical Practice, Non-Interventional Study. PLoS One. 2017;12(6):e0179308. https://doi.org/10.1371/journal.pone.0179308..
DOI: 10.1371/journal.pone.0179308
Weinblatt M.E., Bathon J.M., Kremer J.M., Fleischmann R.M., Schiff M.H., Martin R.W. et al. Safety and Efficacy of Etanercept beyond 10 Years of Therapy in North American Patients with Early and Longstanding Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2011;63(3):373-382. https://doi.org/10.1002/acr.20372..
DOI: 10.1002/acr.20372
Cantini F., Niccoli L., Goletti D. Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. J Rheumatol Suppl. 2014;91:47-55. https://doi.org/10.3899/jrheum.140102..
DOI: 10.3899/jrheum.140102
Насонов Е.Л., Козлов Р.С., Якушин С.Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден -значит вооружен. Клиническая микробиология и антимикробная химиотерапия. 2006;8(4):314-324. Режим доступа: https://cmac-journal.ru/publication/2006/4/cmac-2006-t08-n4-p314/.https://cmac-journal.ru/publication/2006/4/cmac-2006-t08-n4-p314/
Насонов Е.Л., Козлов Р.С., Якушин С.Б. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден -значит вооружен. Клиническая микробиология и антимикробная химиотерапия. 2006;8(4):314-324. Режим доступа: https://cmac-journal.ru/publication/2006/4/cmac-2006-t08-n4-p314/.https://cmac-journal.ru/publication/2006/4/cmac-2006-t08-n4-p314/
Tubach F., Salmon D., Ravaud P, Allanore Y., Goupille P, Breban M. et al. Risk of Tuberculosis Is Higher with Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy Than with Soluble Tumor Necrosis Factor Receptor Therapy: The Three-Year Prospective French Research Axed on Tolerance of Biotherapies Registry. Arthritis Rheum. 2009;60(7):1884-1894. https://doi.org/10.1002/art.24632..
DOI: 10.1002/art.24632
Smolen J.S., Szumski A., Koenig A.S., Jones T.V., Marshall L. Predictors of Remission with Etanercept-Methotrexate Induction Therapy and Loss of Remission with Etanercept Maintenance, Reduction, or Withdrawal in Moderately Active Rheumatoid Arthritis: Results of the PRESERVE Trial. Arthritis Res Ther. 2018;20(1):8. https://doi.org/10.1186/s13075-017-1484-9..
DOI: 10.1186/s13075-017-1484-9
Tanaka Y, Smolen J.S., Jones H., Szumski A., Marshall L., Emery P. The Effect of Deep or Sustained Remission on Maintenance of Remission after Dose Reduction or Withdrawal of Etanercept in Patients with Rheumatoid Arthritis. Arthritis Res Ther 2019;21(1):164. https://doi.org/10.1186/s13075-019-1937-4..
DOI: 10.1186/s13075-019-1937-4
Von Richter O., Skerjanec A., Afonso M., Sanguino Heinrich S., Poetzl J., Woehling H. et al. GP2015, a Proposed Etanercept Biosimilar: Pharmacokinetic Similarity to Its Reference Product and Comparison of Its Autoinjector Device with Prefilled Syringes. Br J Clin Pharmacol. 2017;83(4):732-741. https://doi.org/10.1111/bcp.13170..
DOI: 10.1111/bcp.13170
Matucci-Cerinic M., Allanore Y., Kavanaugh A., Buch M.H., Schulze-Koops H., Kucharz EJ. et al. Efficacy, Safety and Immunogenicity of GP2015, an Etanercept Biosimilar, Compared with the Reference Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 24-Week Results from the Comparative Phase III, Randomised, Double-Blind EOUIRA Study. RMD Open. 2018;4(2):e000757. https://doi.org/10.1136/rmdopen-2018-000757..
DOI: 10.1136/rmdopen-2018-000757
Jaworski J., Matucci-Cerinic M., Schulze-Koops H., Buch M.H., Kucharz E.J., Allanore Y. et al. Switch from Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results from the Phase III, Randomized, Double-Blind EOUIRA Study. Arthritis Res Ther. 2019;21(1):130. https://doi.org/10.1186/s13075-019-1907-x..
DOI: 10.1186/s13075-019-1907-x
Griffiths C.E.M., Thagi D., Gerdes S., Arenberger P., Pulka G., Kingo K. et al. The EGALITY Study: A Confirmatory, Randomized, Double-Blind Study Comparing the Efficacy, Safety and Immunogenicity of GP2015, a Proposed Etanercept Biosimilar, vs. the Originator Product in Patients with Moderate-To-Severe Chronic Plaque-Type Psoriasis. Br J Dermatol. 2017;176(4):928-938. https://doi.org/10.1111/bjd.15152..
DOI: 10.1111/bjd.15152
Kavanaugh A., Allanore Y., Kucharz EJ., Babic G. Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study [abstract]. Arthritis Rheumatol. 2017;69(10 Suppl.). Available at: https://acrabstracts.org/abstract/etanercept-biosimilar-gp2015-has-equiva-lent-efficacy-and-safety-to-etanercept-originator-in-patients-with-moder-ate-to-severe-rheumatoid-arthritis-the-phase-3-equira-study/.https://acrabstracts.org/abstract/etanercept-biosimilar-gp2015-has-equiva-lent-efficacy-and-safety-to-etanercept-originator-in-patients-with-moder-ate-to-severe-rheumatoid-arthritis-the-phase-3-equira-study/
Kavanaugh A., Allanore Y., Kucharz EJ., Babic G. Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study [abstract]. Arthritis Rheumatol. 2017;69(10 Suppl.). Available at: https://acrabstracts.org/abstract/etanercept-biosimilar-gp2015-has-equiva-lent-efficacy-and-safety-to-etanercept-originator-in-patients-with-moder-ate-to-severe-rheumatoid-arthritis-the-phase-3-equira-study/.https://acrabstracts.org/abstract/etanercept-biosimilar-gp2015-has-equiva-lent-efficacy-and-safety-to-etanercept-originator-in-patients-with-moder-ate-to-severe-rheumatoid-arthritis-the-phase-3-equira-study/